Continuous treatment with lenalidomide in multiple myeloma: a case report

We present the case of a 72-year-old woman diagnosed with multiple myeloma (MM) in 1992 and treated with lenalidomide plus dexamethasone (LD) as third-line therapy. The patient achieved a complete remission (CR) after 6 cycles of LD treatment, was treated with LD for almost 4 years, and has now been in CR for 5 years. This case illustrates the potential of lenalidomide for continuous treatment in MM, with side effects controllable through tailored patient management including step-wise dose adaptations.